2013 Deloitte UK Technology Fast 50 Announced
News Dec 09, 2013
Horizon Discovery has announced that it ranked Number 22 in the 2013 Deloitte Technology Fast 50, a ranking of the 50 fastest-growing technology companies in the UK. Rankings are based on percentage revenue growth over five years. Horizon grew 1027% percent during this period.
Horizon’s CEO, Dr. Darrin Disley, credits a rapid increase in exports and a strong, innovative product portfolio with the company’s 1027% revenue growth over the past five years.
Darrin commented: "It is a real testament to the strength of Horizon that we have been so highly amongst such an incredible range of technology companies, and that we are the highest ranked company in the biotechnology sector. I would like to take this opportunity to thank our partners, investors, employees and customers for their support in helping to build a great business. Horizon has much more planned in the months and years to come and we’re very excited about what comes next."
David Halstead, Partner leading the Deloitte Technology Fast 50, said: “The Deloitte Technology Fast 50 gives great profile to technology companies and is internationally recognized as being one of the most important business awards in the sector.”
“Making the Deloitte Technology Fast 50 is a testament to a company’s commitment to technology,” said David, who is also Deloitte Technology partner for the Cambridge region. “With its 1027% growth rate over five years, Horizon Discovery has proven that its leadership has the vision and determination to grow in competitive conditions.”
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE